SNT Share Price Performance
Recent SNT News & Updates
No updates
Syntara Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.0068
- Gross Margin
- -2.82%
- Net Profit Margin
- -135.30%
- Debt/Equity Ratio
- 0.9%
Syntara Limited Competitors
About SNT
- Founded
- 1998
- Employees
- 21
- CEO
- WebsiteView website
Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.5%
- 1 Year: 8.6%
- Year to Date: 5.1%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.2%. Meanwhile, the market is actually up 8.6% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading